This overexpression occurs in around 20–30% of breast cancer cases [4], categorizing it as the HER2-enriched subtype, and although historically associated with poor prognosis, HER2-targeted therapies have shown significant improvements in survival, both in the metastatic and early stages [5,6]. The gene discussed is ERBB2; the disease is breast cancer.